| 前收市價 | 4.1400 |
| 開市 | 4.0200 |
| 買盤 | 3.8900 x 1800 |
| 賣出價 | 3.9700 x 1600 |
| 今日波幅 | 3.9200 - 4.1200 |
| 52 週波幅 | 1.6400 - 4.3000 |
| 成交量 | |
| 平均成交量 | 13,268,942 |
| 市值 | 2.314B |
| Beta 值 (5 年，每月) | 0.61 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -0.3200 |
| 業績公佈日 | 2024年5月02日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 5.79 |
InvestorPlace3 Red-Hot Biotech Rockets Blasting Off in 2024
The economy is currently on a stable trajectory and is poised for sustained growth; the indicators show a positive outlook overall. However, the biotech industry presents even more compelling potential, demonstrating a compounding annual growth rate (CAGR) of 13.96% from 2024 to 2030. This substantial growth is largely attributed to robust government support and the expanding field of personalized medicine, which creates ample opportunities for innovation and advancement. These pivotal factors e
ZacksBiotech Stock Roundup: GERN, CRNX Gain on Updates, BMY's CAR T Cell Therapy News & More
Geron Corporation (GERN) and Crinetics Pharmaceuticals (CRNX) gain on positive regulatory and study updates.
ZacksGeron (GERN) Gets ODAC Votes for Blood Disorder Drug, Shares Up
Geron's (GERN) pipeline candidate, imetelstat, gets FDA Committee backing for the treatment of transfusion-dependent (TD) anemia in adult patients with low-to-intermediate-1 risk myelodysplastic syndromes.
